1. Home
  2. TISI vs MGNX Comparison

TISI vs MGNX Comparison

Compare TISI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TISI
  • MGNX
  • Stock Information
  • Founded
  • TISI 1973
  • MGNX 2000
  • Country
  • TISI United States
  • MGNX United States
  • Employees
  • TISI N/A
  • MGNX N/A
  • Industry
  • TISI Other Consumer Services
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TISI Consumer Discretionary
  • MGNX Health Care
  • Exchange
  • TISI Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • TISI 92.9M
  • MGNX 87.7M
  • IPO Year
  • TISI N/A
  • MGNX 2013
  • Fundamental
  • Price
  • TISI $19.61
  • MGNX $1.33
  • Analyst Decision
  • TISI
  • MGNX Hold
  • Analyst Count
  • TISI 0
  • MGNX 9
  • Target Price
  • TISI N/A
  • MGNX $5.33
  • AVG Volume (30 Days)
  • TISI 17.3K
  • MGNX 2.0M
  • Earning Date
  • TISI 08-07-2025
  • MGNX 08-05-2025
  • Dividend Yield
  • TISI N/A
  • MGNX N/A
  • EPS Growth
  • TISI N/A
  • MGNX N/A
  • EPS
  • TISI N/A
  • MGNX N/A
  • Revenue
  • TISI $851,327,000.00
  • MGNX $154,050,000.00
  • Revenue This Year
  • TISI N/A
  • MGNX N/A
  • Revenue Next Year
  • TISI N/A
  • MGNX N/A
  • P/E Ratio
  • TISI N/A
  • MGNX N/A
  • Revenue Growth
  • TISI N/A
  • MGNX 255.31
  • 52 Week Low
  • TISI $7.65
  • MGNX $0.99
  • 52 Week High
  • TISI $26.77
  • MGNX $5.77
  • Technical
  • Relative Strength Index (RSI)
  • TISI 48.99
  • MGNX 41.45
  • Support Level
  • TISI $18.13
  • MGNX $1.33
  • Resistance Level
  • TISI $20.98
  • MGNX $2.17
  • Average True Range (ATR)
  • TISI 1.16
  • MGNX 0.17
  • MACD
  • TISI 0.15
  • MGNX -0.02
  • Stochastic Oscillator
  • TISI 69.49
  • MGNX 2.38

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: